Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bazedoxifene Acetate

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Bazedoxifene Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Postmenopausal osteoporosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective estrogen receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bazedoxifene Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bazedoxifene Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

    NCT00242710 · start 2005-09

    Registered record
    Registry ID
    NCT00242710
    Conditions
    Endometrial Hyperplasia; Osteoporosis
    Interventions
    Bazedoxifene/Conjugated Estrogen; Bazedoxifene/Conjugated Estrogen; CE 0.45 mg/MPA 1.5mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-09
    Completion
    2008-09
    Enrolment
    1,083

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Hyperplasia; Osteoporosis
    InterventionBazedoxifene/Conjugated Estrogen; Bazedoxifene/Conjugated Estrogen; CE 0.45 mg/MPA 1.5mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.

    NCT00238745 · start 2003-08

    Registered record
    Registry ID
    NCT00238745
    Conditions
    Postmenopausal Osteoporosis
    Interventions
    Bazedoxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-08
    Completion
    2007-03
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopausal Osteoporosis
    InterventionBazedoxifene; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

    NCT00675688 · start 2002-04

    Registered record
    Registry ID
    NCT00675688
    Conditions
    Endometrial Hyperplasia; Osteoporosis
    Interventions
    Bazedoxifene/Conjugate Estrogens (CE); Raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-04
    Completion
    2006-01
    Enrolment
    3,544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Hyperplasia; Osteoporosis
    InterventionBazedoxifene/Conjugate Estrogens (CE); Raloxifene; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

    NCT00205777 · start 2001-12

    Registered record
    Registry ID
    NCT00205777
    Conditions
    Osteoporosis
    Interventions
    Bazedoxifene Acetate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-12
    Completion
    2010-09
    Enrolment
    7,609

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionBazedoxifene Acetate; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women

    NCT00481169 · start 2001-07

    Registered record
    Registry ID
    NCT00481169
    Conditions
    Osteoporosis
    Interventions
    Bazedoxifene Acetate (TSE-424)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-07
    Completion
    2004-09
    Enrolment
    1,742

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionBazedoxifene Acetate (TSE-424)
    PhasePhase 3
    Registry statusCompleted